Pharmaceutical Composition for Resistant Bacterial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing problem of partial and total resistance to therapeutic agents leads to the need for higher doses, resulting in undesirable side effects and toxicity, especially in immunocompromised patients, and can lead to multi-drug resistance, making treatment of infections caused by resistant germs challenging.
Innovation Solution
A pharmaceutical composition combining a first therapeutically active substance, such as carvacrol or alpha-ionone, with a second antibiotic substance, like amoxicillin, to potentiate the antibiotic's activity, allowing for lower doses and effective treatment of resistant bacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the dose of therapeutic agent is increased to overcome partial resistance, then the therapeutic effectiveness is improved, but the toxicity and side effects increase
Solution Approach 1:
The patent combines a known antibiotic with a naturally occurring compound (carvacrol, carvacrol, thymol, or eugenol) to create a synergistic effect. This combination allows the antibiotic to work more effectively at lower doses, thereby maintaining therapeutic effectiveness while reducing toxicity and side effects associated with high-dose monotherapy.
Solution Approach 2:
The invention changes the dosing parameters by using sub-inhibitory concentrations of the natural compound in combination with reduced doses of the antibiotic. This parameter change achieves the desired therapeutic effect while staying below the toxic threshold, effectively resolving the contradiction between effectiveness and safety.
2Reliability
If the dose of therapeutic agent is continuously increased to overcome resistance, then the therapeutic effectiveness is maintained, but the development of total and multi-drug resistance accelerates
Solution Approach 1:
The patent converts the potentially harmful effect of resistance development into a benefit by using a multi-component approach. The natural compound (carvacrol, carvacrol, thymol, or eugenol) works through a different mechanism than traditional antibiotics, thereby bypassing existing resistance mechanisms and preventing the selection of resistant mutants while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention creates a composite therapeutic agent combining a conventional antibiotic with a natural compound. This composite approach addresses resistance by utilizing multiple mechanisms of action, where the natural compound enhances the antibiotic's effectiveness and prevents resistance development, thereby maintaining long-term therapeutic reliability without accelerating resistance.
3Reliability
If high doses of therapeutic agents are administered to treat resistant infections, then the immediate therapeutic effect is improved, but the long-term prognosis and life expectancy of immunocompromised patients deteriorate
Solution Approach 1:
The patent merges a conventional antibiotic with a natural compound (carvacrol, carvacrol, thymol, or eugenol) to achieve both immediate and long-term therapeutic benefits. The combination provides rapid effectiveness at low doses while minimizing toxicity, thereby improving both short-term outcomes and long-term prognosis for immunocompromised patients.
Solution Approach 2:
The invention optimizes dosing parameters by using low doses of the antibiotic in combination with sub-inhibitory concentrations of the natural compound. This parameter optimization achieves immediate therapeutic effects while reducing cumulative toxicity, thereby extending the treatment duration and improving long-term life expectancy without compromising immediate effectiveness.
Data Source
AI summary
The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antibiotic.